Telomerase reverse transcriptase – Wikipedia

Catalytic subunit of the enzyme telomerase Telomerase reverse transcriptase (abbreviated to TERT, or hTERT in humans) is a catalytic subunit of the enzyme telomerase, which, together with the telomerase RNA component (TERC), comprises the most important unit of the telomerase complex.[5][6] Telomerases are part of a distinct subgroup of RNA-dependent polymerases. Telomerase lengthens telomeres in DNA strands, thereby allowing senescent cells that would otherwise become postmitotic and undergo apoptosis to exceed the Hayflick limit and become potentially immortal, as is often the case with cancerous cells. To be specific, TERT is responsible for catalyzing the addition of nucleotides in a TTAGGG sequence to the ends of a chromosome's telomeres.[7] This addition of repetitive DNA sequences prevents degradation of the chromosomal ends following multiple rounds of replication.[8] hTERT absence (usually as a result of a chromosomal mutation) is associated with the disorder Cri du chat.[9][10] Telomerase is a ribonucleoprotein polymerase that maintains telomere ends by addition of the telomere repeat TTAGGG

Read more
Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products – Business Wire

SEATTLE & SEOUL, South Korea--(BUSINESS WIRE)--Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA. The US accounts for nearly 50% of the global stem cell market, and the Celogics joint venture partnership with market leader Curi Bio will represent a major strategic entry for Nexel into the US

Read more
Diabetes – A Closer Look at Stem Cells

How is diabetes treated? Type 1 diabetes patients are given insulin to help them control their glucose levels. These patients, however, often struggle to optimally balance their blood sugar and they need to monitor their blood sugar multiple times a day

Read more
RxCell Inc., A*STAR’s IMCB, NUS, and SERI Collaborate to Develop Cellular Therapeutics for Age-related Diseases – Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--RxCell, a Bay Area-based biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC), together with the Agency for Science, Technology and Research (A*STAR)s Institute of Molecular and Cell Biology (IMCB), Yong Loo Lin School of Medicine at the National University of Singapore (NUS) and the Singapore Eye Research Institute (SERI), announced a co-funded collaboration to develop cellular therapeutics for age-related diseases.

Read more
Singapore-US to develop cellular therapeutics for age-related diseases – BSA bureau

RxCell to establish a Joint Lab to work with IMCB, A*STAR, NUS and SERI in Singapore RxCell, a US-based biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC), together with the Agency for Science, Technology and Research (A*STAR)s Institute of Molecular and Cell Biology (IMCB), Yong Loo Lin School of Medicine at the National University of Singapore (NUS) and the Singapore Eye Research Institute (SERI), has announced a co-funded collaboration to develop cellular therapeutics for age-related diseases. Through this collaboration, RxCell will contribute their clinical grade iPSC as well as hypoimmunogenic iPSC generated by their proprietary technologies which confer the advantage of being able to evade the hosts immune system and avoid an unwanted immune response. This will complement IMCBs expertise in retinal diseases and animal modelling, NUSs expertise in age-related cell therapy strategies and SERIs expertise in rabbits and non-human primates ocular disease models

Read more
Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development – GlobeNewswire

Gosselies, Belgium, 12 October 2021, 7:00 am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed key experts to a Scientific Advisory Board (SAB). Bone Therapeutics has appointed the members of this SAB specifically to provide additional expert guidance on the development of Bone Therapeutics novel, next generation induced pluripotent stem cell-derived mesenchymal stromal cell (iMSC) platform.

Read more
Stem Cells & Therapies Archives – Charlotte Lozier Institute

The California based City of Hope, one of the countrys leading cancer research hospitals, recently sent out birthday greetings to the California Institute for Regenerative Medicine (CIRM), the nations leading funder apart from the federal government of stem cell research. On its 10th birthday, the California Institute for Regenerative Medicine celebrated 10 stem cell therapies that have been approved for clinical trials, including an HIV/AIDS trial at City of Hope, the message read

Read more